Cancer immunotherapy using CD19-directed chimeric antigen receptors
US11154575B2 · kind B2 · utility
4Cited by
65References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 4, 2020 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Nov 4, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.